HCPCS Level II code C1719 identifies a single non-stranded, non-high dose rate iridium-192 brachytherapy source used in radiation oncology. The code is relevant to facilities and clinicians that provide brachytherapy implants for localized cancer treatment, as it specifies supply billing for individual radioactive sources. Nationally, accurate coding of brachytherapy sources affects facility billing, inventory reporting, and payer coverage decisions for oncologic procedures.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will learn the clinical context of C1719, the typical sites of service where these sources are used, and the billing considerations tied to per-source supply reporting. The publication also summarizes common modifiers and payer coverage patterns where available and highlights policy and documentation areas that affect claim adjudication.

This summary provides benchmarks and policy-oriented detail to help revenue cycle managers, coding professionals, and radiation oncology administrators understand where C1719 fits in service lines, how it is documented on the claim, and what payer categories are most relevant for coverage and reimbursement considerations. Data not available in the input is noted where applicable.